GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Ending Cash Position

Medivir AB (Medivir AB) Ending Cash Position : $16.53 Mil (As of Dec. 2023)


View and export this data going back to . Start your Free Trial

What is Medivir AB Ending Cash Position?

Medivir AB's Ending Cash Position for the quarter that ended in Dec. 2023 was $16.53 Mil.

Medivir AB's quarterly Ending Cash Position declined from Jun. 2023 ($7.69 Mil) to Sep. 2023 ($5.51 Mil) but then increased from Sep. 2023 ($5.51 Mil) to Dec. 2023 ($16.53 Mil).

Medivir AB's annual Ending Cash Position declined from Dec. 2021 ($24.33 Mil) to Dec. 2022 ($11.32 Mil) but then increased from Dec. 2022 ($11.32 Mil) to Dec. 2023 ($16.53 Mil).

Medivir AB Ending Cash Position Historical Data

The historical data trend for Medivir AB's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Medivir AB Ending Cash Position Chart

Medivir AB Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Ending Cash Position
Get a 7-Day Free Trial Premium Member Only Premium Member Only 14.26 8.37 24.33 11.32 16.53

Medivir AB Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Ending Cash Position Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 11.32 9.62 7.69 5.51 16.53

Medivir AB Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Medivir AB's Ending Cash Position for the fiscal year that ended in Dec. 2023 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=11.448+5.078
=16.53

Medivir AB's Ending Cash Position for the quarter that ended in Dec. 2023 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=5.957+10.569
=16.53

Medivir AB Ending Cash Position Related Terms

Thank you for viewing the detailed overview of Medivir AB's Ending Cash Position provided by GuruFocus.com. Please click on the following links to see related term pages.

Medivir AB (Medivir AB) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Medivir AB (OTCPK:MVRBF) » Definitions » Ending Cash Position
Comparable Companies
OSTO:SYNACT OSTO:ACE XSAT:HAMLET B XSAT:CURAS OSTO:IVACC OSTO:MAGLE OSTO:CLBIO OSTO:NICA OSTO:IMMU OSTO:SANION OCSE:NOVO B VRTX REGN ASX:CSL XKRX:207940 MRNA XKRX:068270 XBRU:ARGX XBRU:UCB BNTX
Traded in Other Exchanges
MVIR:Sweden MVR0:Germany
Address
Lunastigen 5, PO Box 1086, 2nd floor, Huddinge, SWE, 141 22
Website
https://www.medivir.com
Medivir AB develops drugs with a focus on cancers where there are medical needs. The company invests in indication areas where available treatment methods are limited or lacking and there are opportunities to offer significant improvements to patients. Medivir focuses on the development of MIV-818, a prodrug that has been designed to provide a targeted anti-tumor effect in the liver while minimizing any side effects. Birinapant, a SMAC mimetic, has been out-licensed for development in combination with IGM antibodies for the treatment of solid tumors.